Development of Polymeric Cargo for Delivery of Photosensitizer in Photodynamic Therapy

Table 1

Approved or currently on-trial PSs [2].

Sensitizer	Trade name	Potential indications	Activation wavelength
HPD (partially purified), porfimer sodium	Photofrin	Cervical endobronchial, oesophageal, bladder, gastric cancer, and brain tumors	630 nm
BPD-MA	Verteporfin	Basal-cell carcinoma	689 nm
m-THPC	Foscan	Head and neck tumors prostate and pancreatic tumors	652 nm
5- ALA	Levulan	Basal-cell carcinoma, head and neck, and gynaecological tumors	635 nm
		Diagnosis of brain, head and neck, and bladder tumors	375~400 nm
5-ALA-methylester	Metvix	Basal-cell carcinoma	635 nm
5-ALA-benzylester	Benzvix	Gastrointestinal cancer	635 nm
5-ALA-hexylester	Hexvix	Diagnosis of bladder tumors	375~400 nm
SnETs	Purlytin	Cutaneous metastatic breast cancer, basal-cell carcinoma, Kaposi’s sarcoma, and prostate cancer	664 nm
Boronated protoporphyrin	BOPP	Brain tumors	630 nm
HPPH	Photochlor	Basal-cell carcinoma	665 nm
Lutetium texaphyrin	Lutex	Cervical, prostate, and brain tumors	732 nm
Phthalocyanine-4	Pc4	Cutaneous/subcutaneous lesions from diverse solid tumor origins	670 nm
Taporfin sodium	Talaporfin	Solid tumors from diverse origins	664 nm

*5-ALA: 5-aminolevulinic acid; BPD-MA: benzoporphyrin derivative-monoacid ring A; HPD: hematoporphyrin derivative; HPPH: 2-(1-Hexyl-oxyethyl)-2-devinyl pyropheophorbide-alpha; mTHPC: meta-tetrahydroxyphenylchlorin; SnET2: tin ethyl etiopurin.